Ellis, Michael J.
Lekka, Christiana
Holden, Katie L.
Tulmin, Hanna
Seedat, Faheem
O’Brien, Darragh P.
Dhayal, Shalinee
Zeissler, Marie-Louise
Knudsen, Jakob G.
Kessler, Benedikt M.
Morgan, Noel G.
Todd, John A.
Richardson, Sarah J.
Stefana, M. Irina http://orcid.org/0000-0002-4796-5884
Funding for this research was provided by:
Wellcome Trust (107212/A/15/Z)
Juvenile Diabetes Research Foundation International (4-SRA-2017-473-A-A, 5-CDA-2014-221-A-N)
Medical Research Council (MR/P010695/1)
Research England
UCB Biopharma
Article History
Received: 7 November 2023
Revised: 3 April 2024
Accepted: 3 April 2024
First Online: 18 May 2024
Declarations
:
: All antibodies mentioned in this manuscript are commercially available. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRoteomics IDEntification Database (PRIDE) [] partner repository with the dataset identifier PXD041199. All other data on which conclusions are based are included within the manuscript and its additional files, and raw data files are available from the corresponding authors upon reasonable request.
: This work was partly funded by a collaborative agreement between the University of Oxford and UCB BioPharma. UCB staff were not involved in the design of the experiments, analysis of the data or interpretation of the results. The authors declare no other competing interests.
: Anonymised human brain tissue was obtained from the Oxford Brain Bank. This material was obtained by Oxford Brain Bank from humans with appropriate consent as required by the Human Tissue Act 2004 and with ethical approval (REC name: South Central – Oxford C; REC ref: 15/SC/0639; IRAS ID: 103696).